Pérez-Regadera Gómez, José FermínSánchez-Muñoz, AlfonsoDe-la-Cruz, JavierBallestín Carcavilla, ClaudioLora Pablos, DavidGarcía-Martín, RosaAlonso-Carrión, LorenzoMendiola Fernández, Dionisio CésarLanzós González, Eduardo2025-01-272025-01-272010-01Pérez-Regadera J, Sánchez-Muñoz A, De-la-Cruz J, Ballestín C, Lora D, García-Martín R, Alonso-Carrión L, Mendiola C, Lanzós E. Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer. Int J Gynecol Cancer. 2010 Jan;20(1):164-72. doi: 10.1111/IGC.0b013e3181ad3e11. PMID: 20057287.1048-891X10.1111/igc.0b013e3181ad3e11https://hdl.handle.net/20.500.14352/116117Objectives: To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment. Methods: A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB [71]; IVA [19]; including both epidermoid [86] and adenocarcinoma [14]) were analyzed to determine c-erb-B2 levels by immunohistochemistry (c-erb-B2 antibody; Dako, Glostrup, Denmark). Only c-erb-B2+++ biopsies were considered positive. All patients received pelvic radiotherapy, brachytherapy, and concurrent chemotherapy with 2 different regimens: 48 patients were treated with tegafur (800 mg/d orally) and 88 with tegafur (same doses) plus 5 cycles of weekly cisplatin 40 mg/m/wk intravenously. Results: A total of 32 (23.5%) biopsies were considered c-erb-B2-positive. Three-year and 5-year DFS were 61% and 58% for c-erb-B2-negative patients and 36% and 36% for c-erB2-positive patients, respectively (P = 0.02). Patients were stratified in 4 groups according to their c-erb-B2 status and whether they received cisplatin. The group of patients with c-erb-B2 overexpression that did not receive platinum treatment had a higher rate of pelvic relapse (P < 0.0001), associated with a decreased DFS (P = 0.0014). Conclusions: c-erb-B2 overexpression may imply a poor prognosis for patients with advanced CC. Treatment with cisplatin-based radiochemotherapy improved outcome in these patients.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal articlehttps://doi.org/10.1111/igc.0b013e3181ad3e11https://pubmed.ncbi.nlm.nih.gov/20057287/https://www.sciencedirect.com/science/article/pii/S1048891X24200530open access615.849.1c-erb-B2 statusDisease-free survivalLocal relapse rateAdvanced cervical cancerChemoradiotherapyOncología3201.12 Radioterapia3201.01 Oncología